RapidPulse raises $10.5M for stroke therapies

2022-09-13

Epidarex Capital, Hatteras Venture Partners and Broadview Ventures also joined the round. It brings RapidPulse’s total funding to more than $25 million. Miami-based RapidPulse develops a novel cyclic aspiration system to treat ischemic stroke. It plans to use funding proceeds to further advance its RapidPulse system through expanded clinical evaluation. In turn, it expects this to further the development and move it toward FDA approval. “RapidPulse has built an excellent team and taken great strides in developing our technology and system architecture; we’ve had three seminal patents issued to protect our intellectual property and we’ve received excellent feedback from some of the leading ischemic stroke physicians,” said Sean McBrayer, who serves as the CEO of RapidPulse as well as CEO of Syntheon. McBrayer pointed to recent clinical results, calling them “outstanding.” Initial testing demonstrated first-pass clot removal of up to 69% of the time. The company said this represents a “dramatic improvement” over standard aspiration. “Stroke is the second leading cause of death and the third leading cause of disability worldwide,” said Dennis McWilliams, Santé Ventures partner. “This investment will help RapidPulse expand its clinical results and move towards regulatory approval in the United States. The RapidPulse system promises to be a disruptive platform in neurovascular, and it has the clear potential to improve timely first-pass clot removal, thereby significantly improving patient outcomes for ischemic stroke patients. “This financing will help RapidPulse build a leading position in the emerging field of cyclic aspiration for the treatment of ischemic stroke.”

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构